The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2020 | Developing and understanding kinase inhibitors to treat CLL
Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, discusses how kinase inhibitors have improved for the treatment of chronic lymphocytic leukemia (CLL) by blocking survival signals. However, some treatments are less effective and these differences need to be explored so they can be considered when designing novel therapies. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
